Il Meeting annuale della European Society of Medical Oncology (ESMO) si è tenuto a Barcellona dal 13 al 17 settembre. Numerose le novità e gli studi presentati: alcuni di essi - i più importanti - vengono collocati come di consuetudine nelle Sessioni Presidenziali e sono esplicitamente definiti “practice changing”. Questi non li possiamo perdere!

Bibliografia

• Gillessen S, et al. A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3. ESMO Congress 2024 – Abstract LBA1
• Rao S, et al. POD1UM-303/InterAACT 2: Phase 3 Study of Retifanlimab with CarboplatinPaclitaxel (C-P) in Patients (Pts) With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC) Not Previously Treated With Systemic Chemotherapy (Chemo). ESMO Congress 2024– Abstract LBA2 
• Lorusso D, et al.  Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOTcx11/GOG-3047/KEYNOTE-A18 study. ESMO Congress 2024 – Abstract 709O
• Llovet J, et al. Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study. ESMO Congress 2024 – Abstract LBA3
• Schmid P, et al. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study. ESMO Congress 2024 – Abstract LBA4
• Rivera S, et al. Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase 3 UNICANCER trial. ESMO Congress 2024 – Abstract 231O 
• Powles T, et al. A randomized phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA). ESMO Congress 2024 – Abstract LBA5